Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.

Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

T1DM Mini-Series: Edition Junior trial results

T1DM Mini-Series: Edition Junior trial results

T1DM Mini-Series: Edition Junior trial results

T1DM Mini-Series: Edition Junior trial results

T1DM Mini-Series: Edition Junior trial results

T1DM Mini-Series: Edition Junior trial results

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines